Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis.

Ellard GA, Ellard DR, Allen BW, Girling DJ, Nunn AJ, Teo SK, Tan TH, Ng HK, Chan SL.

Am Rev Respir Dis. 1986 Jun;133(6):1076-80.

PMID:
3717760
2.

Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.

Gurumurthy P, Ramachandran G, Vijayalakshmi S, Kumar AK, Venkatesan P, Chandrasekaran V, Vjayasekaran V, Kumaraswami V, Prabhakar R.

Int J Tuberc Lung Dis. 1999 Feb;3(2):119-25.

PMID:
10091876
5.

Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.

Acocella G, Luisetti M, Grassi GG, Peona V, Pozzi E, Grassi C.

Monaldi Arch Chest Dis. 1993;48(3):205-9.

PMID:
8369784
8.

Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.

Agrawal S, Singh I, Kaur KJ, Bhade SR, Kaul CL, Panchagnula R.

Int J Clin Pharmacol Ther. 2002 Oct;40(10):474-81.

PMID:
12395981
10.
11.

Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.

Xu J, Jin H, Zhu H, Zheng M, Wang B, Liu C, Chen M, Zhou L, Zhao W, Fu L, Lu Y.

Clin Ther. 2013 Feb;35(2):161-8. doi: 10.1016/j.clinthera.2013.01.003.

PMID:
23410999
12.

Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.

Zwolska Z, Niemirowska-Mikulska H, Augustynowicz-Kopec E, Walkiewicz R, Stambrowska H, Safianowska A, Grubek-Jaworska H.

Int J Tuberc Lung Dis. 1998 Oct;2(10):824-30.

PMID:
9783530
13.
15.

Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.

Bekker A, Schaaf HS, Draper HR, van der Laan L, Murray S, Wiesner L, Donald PR, McIlleron HM, Hesseling AC.

Antimicrob Agents Chemother. 2016 Mar 25;60(4):2171-9. doi: 10.1128/AAC.02600-15. Print 2016 Apr.

16.

Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.

Agrawal S, Kaur KJ, Singh I, Bhade SR, Kaul CL, Panchagnula R.

Int J Pharm. 2002 Feb 21;233(1-2):169-77.

PMID:
11897421
17.

[Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].

Brändli O, Haegi V, Villiger B, Bohn W, Baumann HR, Zäch R.

Schweiz Med Wochenschr. 1989 Mar 11;119(10):299-305. German.

PMID:
2652281
18.
19.

Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?

Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL.

Am J Respir Crit Care Med. 2008 Nov 1;178(9):989-93. doi: 10.1164/rccm.200807-1029OC. Epub 2008 Aug 21.

20.

Evaluation of bioequivalence of isoniazid and pyrazinamide in three and four drugs fixed dose combinations using WHO simplified protocol.

Panchagnula R, Sancheti P, Rungta S, Agrawal S, Kaul CL.

Pharmacol Res. 2003 Oct;48(4):383-7.

PMID:
12902209

Supplemental Content

Support Center